Frontier Pharma Report: Transplantation Therapeutics Market 2017 - Chemokines and Immune Surface Antigens Appear to Hold Promise as Novel Targets

World News: . []

Dublin, April 17, 2018 (GLOBE NEWSWIRE) -- The report has been added to offering.

This report helps to identify innovative pipeline programs across a therapy area, with a focus on indications with high R&D activity and strong innovation, as well as a competitive commercial landscape and high levels of deal activity. Monitoring innovative new product developments is becoming an increasingly vital part of competitive intelligence for all market participants, and increasingly important for companies seeking strategic partnerships or looking to acquire technologies, products or other companies.

In 2015, more than of 125,000 transplantations were performed worldwide, an increase of over 5.5% from 2014, with around 33,000 of these occurring in the EU and a further 32,000 in the US. Approximately 60% of these were kidney transplants, with liver, heart, lung, pancreas and small bowel transplantations accounting for the other most common procedures.Generally, there are a modest number of safe pharmacological treatment options for acute rejections, but long-term treatment options remain unsatisfactory. The risk of infection limits the effectiveness of these therapies, and improvements to their efficacy are needed regardless. Specific transplantation tolerance, in which alloreactive T cells are inactivated while the broader immune response is left intact, removing the need for broad immunosuppressant therapies, can be considered as an end-goal for clinical transplantation.Compared with the overall immunology pipeline, in which there are over 1,900 products, the transplantation pipeline is small, with only about 244 products. However, of the 145 products in the transplantation pipeline with a disclosed molecular target, there are 65 first-in-class products, acting on a total of 63 first-in-class targets. First-in-class products account for 44% of transplantation pipeline products with a disclosed molecular target.Of the 65 first-in-class pipeline products in development for transplantation and GVHD, those which emerged as being the most promising based on underlying scientific data included cell surface antigens such as CD40 and 47, and chemokines such as CXCR1 and 2. Many of these have yielded promising Preclinical data, although the availability of published clinical data is limited. Nonetheless, many drugs have reached a late stage of development, such as Dompe Farmaceutica's reparixin, and appear poised to be valuable additions to the relatively stagnant range of treatments for the prevention of transplant rejection, and if successful will be able to drive higher long-term post-transplant survival rates.

For more information about this report visit




CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Liver and Kidney Disorders Drugs , Immunosuppressive Drugs

More news and information about Research and Markets

Published By:

Globe Newswire: 09:21 GMT Tuesday 17th April 2018

Published: .

Search for other references to "frontier" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us
 

Advertising on SPi News: Information For Advertisers